Objective: To describe the characteristics and clinical course of febrile neutropenia (FN) in pediatric patients admitted to a comprehensive cancer center in Jordan.
F ever is a well-recognized complication in cancer patients with neutropenia. Febrile episodes were reported in 34% of neutropenic children with chemotherapy-induced neutropenia or after hematopoietic stem cell transplantation. 1 Less than 1 febrile episode is expected for every 30 neutropenic days at risk and the incidence, and the rate of febrile complications vary according to the type of chemotherapy. 1 Although several studies have described the etiology, characteristics, and outcomes of febrile neutropenia (FN) in pediatric cancer patients in the developed countries, 1-9 very few studies have described this common complication in pediatric patients in the Middle East. [10] [11] [12] In addition, the previous studies from the Middle East were conducted more than a decade ago and therefore, the data may not be reflective of the current situation. In fact, one study demonstrated a change in the pattern of blood stream infections in pediatric cancer patients when comparing data from 1992 to 1994 and 1998 to 2000 at the same institution. 12 Therefore, we conducted this study to describe the characteristics and clinical outcomes of pediatric patients admitted with FN. The study was conducted at a comprehensive cancer center in Jordan, King Hussein Cancer Center (KHCC), which is the only specialized center in the country and treats patients from Jordan and the surrounding region.
METHODS
This was a 6-month prospective observational study conducted at KHCC between October, 2010, and March, 2011. KHCC is a 170-bed comprehensive teaching cancer center, treating over 3000 new cases of adult and pediatric cancer patients each year from Jordan and the surrounding countries.
Patients with underlying malignancies who were <20-year-old and were admitted to the pediatric ward, which includes 35 beds for oncology non-bone marrow transplant patients, at KHCC, with the diagnosis of FN were identified by daily review of the medical records. Patients who developed >1 episode of FN during the study period were included in the study. The medical records of the enrolled episodes were reviewed for demographic data, last date of chemotherapy administered, date of admission, length of hospital stay, absolute neutrophil count (ANC) findings, duration of neutropenia, presence of central venous catheter (CVC), documented microbiological infections, transfer to the intensive care unit (ICU), mortality, and use of granulocyte colony-stimulating factor (G-CSF), either as prophylaxis 24 hours after the last dose of chemotherapy or as treatment in patients who already developed FN and G-CSF was not part of their chemotherapy protocol.
According to KHCC's guidelines, investigations for all FN patients are initiated immediately. The initial investigations include complete blood count with differential count, renal and liver function tests, and blood cultures collected in continuously-read BACTEC bottles. Chest x-ray is obtained for patients with respiratory symptoms. Any suspicious discharge is sent for bacterial and fungal culture. In patients with diarrhea, stool samples are sent for microscopic analysis and culture and sensitivity testing; the presence of ova and parasites, Clostridium difficile toxins, rotavirus, adenovirus, and cryptosporidium was tested by antigen detection.
Patients with FN are managed according to the institutional FN guidelines, which are adopted from the 2002 guidelines of the Infectious Disease Society of America. 13 The guidelines recommend the initiation of intravenous (IV) piperacillin/tazobacatam 100 mg/kg/dose (maximum dose of 4500 mg) every 6 hours and IV amikacin 15 mg/kg/ dose (maximum dose of 1000 mg) every 24 hours. Glycopeptides (vancomycin or teicoplanin) are added if any of the following is found: known patient colonization with a resistant gram-positive organism such as methicillin-resistant Staphylococcus aureus or penicillin-resistant Streptococcus pneumoniae, severe mucositis (grade 3 to 4), hypotension (systolic blood pressure < fifth percentile for age and sex), or clinical evidence of CVC-related infection such as drainage from the CVC or erythema around the CVC. Empirical antifungal therapy is considered in patients with persistent fever that is not responding to broad spectrum antibiotics after 5 to 7 days or in the following situations: the presence of signs and/or symptoms suggestive of fungal infection, previous history of documented invasive fungal infection, or positive cultures and/or histopathologic analysis for molds. Conventional amphotericin B is used as the first-line treatment. For patients with a clinical picture suggestive of viral infection, antiviral medications are started with IV acyclovir being the first drug of choice. Patients who are afebrile for at least 48 hours from the start of IV antibiotics may be considered for early discharge on oral antibiotics. Antifungal or antiviral prophylaxis is not administered routinely and screening radiologic studies are not carried out unless needed.
Chemotherapy is administered either in the inpatient or the outpatient settings. For patients with acute leukemia, induction chemotherapy is initiated in the inpatient setting until the patient condition is stabilized, and he/she can be safely discharged home to complete chemotherapy in the outpatient setting.
According to KHCC's guidelines, G-CSF may be prescribed in the following cases: as primary prophylaxis in high-risk patients with an expected incidence of FN of Z40%, or in patients likely to require prolonged hospitalization such that the hospital stay and cost would probably exceed the cost of 10 to 14 days of G-CSF administration. G-CSF may also be prescribed as secondary prophylaxis in the setting of curable tumors (eg, germcell tumors, lymphomas) where dose reduction or delay of chemotherapy may compromise the survival of patients; in such a setting, secondary G-CSF prophylaxis is given in later cycles after an episode of FN has occurred in an attempt to maintain chemotherapy dose/schedule. Routine use of G-CSF in patients who already developed FN is not recommended, except in certain patients who may be at a higher risk of infection-associated complications and have prognostic factors that are predictive of poor outcomes (eg, sepsis, pneumonia, hypotension, multiorgan dysfunction, or invasive fungal infection). G-CSF is used at a dose of 5 mcg/kg/day subcutaneously.
Definitions
Fever was defined as a single oral temperature measurement Z38.3 1C in the absence of obvious environmental causes or a sustained oral temperature Z38.01C for >1 hour. FN was defined as ANC r500 (or a count of <1000 with a predicted decrease to <500) and fever as defined previously.
Microbiologically documented infection (MDI) with bacteremia was defined as isolation of a significant pathogen from one or more blood cultures. MDI without bacteremia was defined as isolation of a significant pathogen from a well-defined site of infection (eg, urine, respiratory secretions, or abscess aspiration obtained with sterile procedures). Clinically documented infection was defined as the presence of a clinical picture that is suggestive of an infection but without microbiologic evidence. Fever of unknown origin (FUO) was defined as lack of clinical and microbiological evidence, but the clinical course was suggestive of an infection.
Statistical Analysis
Nominal data was presented as counts and percentages, whereas continuous data was presented as medians, means, range, and SD. A univariate analysis was performed to evaluate the association between MDI and episoderelated factors. A w 2 test or a t test was used, as appropriate, and a significance criterion of Pr0.05 was used in the analysis. All analysis was performed using SAS version 9.1 (SAS Institute Inc., Cary, NC).
RESULTS
During the study period, a total of 109 episodes of FN for 88 patients were evaluated. Characteristics of these episodes are shown on Table 1 .
Over half of the FN episodes (54%) had profound neutropenia (ANC < 100 cells/mm ) and a median duration of neutropenia of 6 days (range, 1 to 31 d).
FUO was reported in 60 episodes (55%). The remaining were clinically documented infections in 29 (26.6%) episodes and MDI in 20 (18.4%) episodes.
The symptoms associated with the clinically documented infections were: respiratory (n = 18, 62.1%), urinary (n = 5, 17.2%), gastrointestinal (n = 5, 17.2%), and 1 episode of mixed urinary and respiratory symptoms (n = 1, 3.5%). MDI with bacteremia was documented in 12 (60%) episodes, gram-positive bacteria were reported in 9 (75%) episodes and included the following: coagulase-negative Staphylococcus (n = 2), Enterococcus faecalis (n = 1), S. saccharolyticus (n = 1), Peptostreptococcus spp. (n = 1), Neisseria cinerea (n = 1), gram-positive Bacillus (n = 1), and Viridans streptococci (n = 1). One episode of MDI with bacteremia was polymicrobial and included: coagulase-negative Staphylococcus and V. streptococci. Gram-negative organisms were reported in 3 episodes (25%) and included Escherichia coli (n = 2) and Klebsiella pneumonia (n = 1).
The MDI without bacteremia was documented in 2 (10%) episodes, 1 episode of Proteus vulgaris isolated from the urine culture and 1 episode of methicillin-resistant S. aureus isolated from a nasal swab culture.
There were 5 (25%) episodes of viral infections and 1 (5%) episode of fungal infection. Viral pathogens identified were influenza B (n = 3), influenza A (n = 1), and influenza A and B (n = 1) viruses, and the one episode of fungal infection was due to Candida lusitaniae.
Transfer to the ICU was required for the management of 12 (11%) episodes of FN. Two of the cases that were transferred to the ICU were associated with gram-positive MDI, whereas the remaining cases were reported as FUO. There were no reported deaths related to FN in any of the patients evaluated during the 6-month period of this study. We reported 2 deaths due to disease progression, 1 patient with osteosarcoma and the other with Ewing sarcoma.
Positive blood cultures were significantly more in episodes with a CVC, compared with episodes with no CVC (52.2% vs. 29.8%; P = 0.04). There was no significant correlation between the presence of MDI and any of the factors studied, which included age, sex, type of malignancy, duration since last chemotherapy, G-CSF administration, and ICU transfer.
DISCUSSION
The epidemiology of FN in pediatric cancer patients in the Middle East is not well studied. The intention of this study was to describe the characteristics of pediatric patients presenting with FN, the pathogens isolated, and the outcomes of the episodes of FN. This will provide a better understanding of the epidemiology of FN in pediatric cancer patients. In addition, it will help in developing risk stratification management in further studies and in choosing the appropriate antimicrobial agents.
Similar to other studies in different regions of the world, 1,4,8,9,14 the etiology of FN was unknown in more than half of our episodes, and the fever was considered as FUO. In previous studies, patients with FUO were found to have less severe clinical course and lower morbidity and mortality. 1, 2, 4, 15 Such data may help in the early stratification of patients presenting with FN.
MDIs were found in 18.4% of our FN episodes, with gram-positive bacteria being the most commonly isolated type of pathogen. This is comparable with what had been found in earlier studies in our region 10, 11 but different from what was described in a more recent study. 12 In their retrospective study on septicemia in febrile neutropenic children with cancer in Saudi Arabia, Al-Fawaz et al 10 found that 54% of the positive blood cultures were gram-positive bacteria followed by gram-negative bacteria in 39.4% and Candida in 6.6% of the episodes. The presence of CVC was not significantly associated with an increase in gram-positive or gram-negative bacterial cultures but was associated with an increased incidence of fungal infections. This finding is different from what we found in our study, where the only statistically significant association with the MDI was the presence of CVC. Two retrospective studies on the pattern of blood stream infections among febrile children with cancer, with or without neutropenia, from Tawam medical center in United Arab Emirates were conducted. 11, 12 The authors reported a higher incidence of gram-positive bacterial infections but the latter study reported a high incidence of polymicrobial bacteria and found that the most common identifiable source of infection was the presence of CVC. In our study, we reported only 1 episode of polymicrobial bacterial infection.
Of the reported MDI in our study, 25% were viral infections. This finding is relatively similar to another study by Hakim et al, 4 which reported 34% of viral infections. Other studies showed lower incidence of viral infections. 1, 9 We contributed the relatively high proportion of viral infections to the influenza season, during which we were actively screening patients for H1N1 infections.
Our study reported no deaths related to FN among the patients. The favorable outcome is different from what has been reported in previous studies from other developing countries. 11, 12, 16, 17 One study on the treatment of children with B-cell non-Hodgkin lymphoma in Iraq showed that 49 deaths out of 69 were related to infections. 16 Another study in El Salvador on the microbiology and mortality in pediatric patients with FN reported 12% mortality rate. 17 Although we had a shorter duration in our study, the favorable outcome in our study can be attributed to the adherence to FN-specific guidelines, the improvement of infection control measures in our center, such as implementing the infection control program to provide an effective hospital mechanism for the surveillance, prevention and control of infections, presence of full-time infection control registered nurses, following all the isolation precautions and the negative pressure rooms, and the early recognition and treatment of patients with FN.
There are a few limitations to the study. First the duration of the study and the number of patients did not clearly describe the epidemiology of FN in pediatrics. Second, we did not analyze factors like the duration of fever, type of chemotherapy, indication of G-CSF, or specific criteria for ICU transfer decision. In addition, the time frame of the study overlapped with the influenza season, which may affect the microbiological profile of the FN episodes.
However, to our knowledge, this is the first study to describe this patient population and therefore provides a general idea about the characteristics and outcomes of FN in pediatric patients in Jordan.
In conclusion, this study demonstrated that most of the pediatric patients admitted with FN had FUO. In developing countries, the rate of mortality during episodes of FN is relatively high in cancer patients, but in this study we demonstrated favorable outcomes. Given the economic burden of treating cancer and its complications, future studies are needed to develop valid and reliable risk stratification models for pediatric patients that would identify low-risk patients and allow outpatient treatment.
